Small Molecule Disaggregases Restore Lens Flexibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia, such as non-invasive devices and invasive surgical procedures, fail to reverse the loss of accommodative ability and do not prevent or delay the onset of the condition, while existing methods for addressing age-related nuclear cataracts are limited in effectiveness.
Innovation Solution
Development of small molecule disaggregases (SMDs) that inhibit the formation of high molecular weight aggregates of alpha-crystallin, which are administered to treat presbyopia and cataracts, using compounds with specific structural formulas to target and prevent the aggregation of alpha-crystallin proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If non-invasive devices are used to improve near and distance vision, then vision quality is improved, but the natural process of accommodation cannot be restored and constant device use is required
Solution Approach 1:
The patent employs small molecule disaggregases that enable the lens to self-regulate its protein aggregation state. These molecules allow the lens to naturally prevent or reverse aggregation without external device intervention, making the eye's accommodation system self-sufficient rather than requiring constant external assistance.
Solution Approach 2:
The patent replaces mechanical/optical devices with a biochemical mechanism. Instead of using physical devices to correct vision, small molecule disaggregases are used to modify the biochemical state of crystallin proteins, enabling pharmacological restoration of accommodation through chemical rather than mechanical means.
2Illumination intensity
If invasive surgical procedures are performed to correct presbyopia, then vision correction is achieved, but complications such as decrease in vision quality, regression effects, anisometropia, corneal ectasia, and haze occur
Solution Approach 1:
The patent replaces invasive mechanical surgical procedures with a biochemical approach. Small molecule disaggregases are administered to modify protein aggregation states, achieving vision correction through pharmacological means rather than physical intervention, thereby avoiding surgical complications.
Solution Approach 2:
The patent changes the biochemical parameters of the lens by introducing small molecules that alter the aggregation state of crystallin proteins. This pharmacological parameter change achieves vision correction without the physical trauma and complications associated with surgical parameter changes.
3Strength
If alpha-crystallin forms high molecular weight aggregates with age, then lens stiffness increases, but accommodative power is lost
Solution Approach 1:
The patent converts the harmful aggregation of alpha-crystallin into a beneficial state by using small molecule disaggregases to reversibly modify the aggregation. Instead of preventing aggregation entirely, the therapy allows controlled aggregation while maintaining flexibility, turning the age-related aggregation process from a harmful factor into a manageable condition that preserves accommodation.
Solution Approach 2:
The patent changes the aggregation parameters of alpha-crystallin by introducing small molecules that modify the aggregation state. This allows the lens to maintain structural integrity through controlled aggregation while preserving accommodative power through pharmacological modulation of aggregation kinetics and reversibility.
4Illumination intensity
If current presbyopia treatments are used, then near and distance vision can be improved, but the onset of presbyopia cannot be prevented or delayed
Solution Approach 1:
The patent employs preliminary action by using small molecule disaggregases to prevent or delay the formation of harmful protein aggregates before they cause irreversible lens stiffening. This proactive biochemical intervention addresses presbyopia at its molecular origin, potentially preventing onset rather than merely correcting symptoms after they appear.
Solution Approach 2:
The patent enables continuous protective action through small molecules that continuously inhibit or reverse protein aggregation. Unlike periodic surgical interventions or daily device use, the pharmacological agent provides ongoing molecular-level protection against aggregation, maintaining lens flexibility continuously over time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SMDs effectively prevent the formation of high molecular weight aggregates of alpha-crystallin, thereby restoring lens flexibility and accommodative power, offering a potential non-invasive treatment for presbyopia and improving outcomes for age-related cataracts.
Implementation Method 1
small molecule disaggregases (SMDs) that can inhibit formation of HMW aggregates human ACC
Implementation Method 2
restoration of lens flexibility is sufficient to restore accommodation
Data Source
AI summary
Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human α-A-crystallin. Compositions containing certain compounds are believed to be also effective in the treatment of transthyretin (TTR)-associated amyloidosis and Parkinson's disease.